Teva Pharmaceutical Industries raised its full-year 2026 revenue guidance, driven by a 43% year-over-year increase in combined revenue from its innovative medicines AUSTEDO, AJOVY, and UZEDY. The company lifted the midpoint of its overall 2026 revenue outlook by $75 million, while second-quarter revenue of approximately $4.1 billion declined 1% from a year earlier as lower sales from generic Revlimid were largely offset by growth in the innovative portfolio. AUSTEDO generated $676 million in U.S. revenue, up 33%, and its full-year guidance was raised to a range of $2.45 billion to $2.6 billion. UZEDY posted quarterly revenue of $77 million, up 43%, with its full-year forecast increased by $15 million at the midpoint to $270 million to $290 million, and AJOVY's global revenue rose 56% to $244 million, prompting a $90 million midpoint increase in its full-year outlook to $850 million to $870 million. Teva reported a GAAP net loss of $576 million, or $0.49 per share, including a $724 million in-process research and development expense from the Emalex Biosciences acquisition, while non-GAAP earnings per share were $0.02, or $0.63 excluding that impact. Free cash flow rose 31% to $622 million, and the company ended the quarter with net debt of $12.9 billion and a net-debt-to-EBITDA ratio of 2.8 times, or 2.3 times excluding the Emalex acquisition.
Teva Pharma Industries Ltd ADRTeva raised 2026 revenue guidance driven by 43% growth in key innovative drugs AUSTEDO, AJOVY, UZEDY.
Teva reported a $724 million in-process R&D expense from the Emalex acquisition, contributing to a GAAP net loss.